Yazbeck R - Search Results

1

Development of a ¹³C Stable Isotope Assay for Dipeptidyl Peptidase-4 Enzyme Activity A New Breath Test for Dipeptidyl Peptidase Activity.

Yazbeck R, Jaenisch S, Squire M, Abbott CA, Parkinson-Lawrence E, Brooks DA, Butler RN. Yazbeck R, et al. Sci Rep. 2019 Mar 20;9(1):4906. doi: 10.1038/s41598-019-41375-y. Sci Rep. 2019. PMID: 30894647 Free PMC article.

2

Dipeptidyl peptidase 4 inhibitors: Applications in innate immunity?

Yazbeck R, Jaenisch SE, Abbott CA. Yazbeck R, et al. Biochem Pharmacol. 2021 Jun;188:114517. doi: 10.1016/j.bcp.2021.114517. Epub 2021 Mar 13. Biochem Pharmacol. 2021. PMID: 33722535 Free PMC article. Review.

3

Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?

Yazbeck R, Howarth GS, Abbott CA. Yazbeck R, et al. Trends Pharmacol Sci. 2009 Nov;30(11):600-7. doi: 10.1016/j.tips.2009.08.003. Trends Pharmacol Sci. 2009. PMID: 19837468 Review.

4

In vitro development and validation of a non-invasive (13)C-stable isotope assay for ornithine decarboxylase.

Jaenisch S, Squire M, Butler R, Yazbeck R. Jaenisch S, et al. Among authors: yazbeck r. J Breath Res. 2016 May 3;10(2):026009. doi: 10.1088/1752-7155/10/2/026009. J Breath Res. 2016. PMID: 27137347

5

Potential disease biomarkers: dipeptidyl peptidase 4 and fibroblast activation protein.

Yazbeck R, Jaenisch SE, Abbott CA. Yazbeck R, et al. Protoplasma. 2018 Jan;255(1):375-386. doi: 10.1007/s00709-017-1129-5. Epub 2017 Jun 16. Protoplasma. 2018. PMID: 28620698 Review.

6

Dipeptidyl peptidases and inflammatory bowel disease.

Abbott CA, Yazbeck R, Geier MS, Demuth HU, Howarth GS. Abbott CA, et al. Among authors: yazbeck r. Adv Exp Med Biol. 2006;575:155-62. doi: 10.1007/0-387-32824-6_16. Adv Exp Med Biol. 2006. PMID: 16700518 Review. No abstract available.

7

Inhibiting dipeptidyl peptidase activity partially ameliorates colitis in mice.

Yazbeck R, Howarth GS, Geier MS, Demuth HU, Abbott CA. Yazbeck R, et al. Front Biosci. 2008 May 1;13:6850-8. doi: 10.2741/3193. Front Biosci. 2008. PMID: 18508699

8

Growth factor based therapies and intestinal disease: is glucagon-like peptide-2 the new way forward?

Yazbeck R, Howarth GS, Abbott CA. Yazbeck R, et al. Cytokine Growth Factor Rev. 2009 Apr;20(2):175-84. doi: 10.1016/j.cytogfr.2009.02.008. Epub 2009 Mar 25. Cytokine Growth Factor Rev. 2009. PMID: 19324585 Review.

9

Dipeptidyl peptidase expression during experimental colitis in mice.

Yazbeck R, Sulda ML, Howarth GS, Bleich A, Raber K, von Hörsten S, Holst JJ, Abbott CA. Yazbeck R, et al. Inflamm Bowel Dis. 2010 Aug;16(8):1340-51. doi: 10.1002/ibd.21241. Inflamm Bowel Dis. 2010. PMID: 20186930

10

Biochemical and histological changes in the small intestine of mice with dextran sulfate sodium colitis.

Yazbeck R, Howarth GS, Butler RN, Geier MS, Abbott CA. Yazbeck R, et al. J Cell Physiol. 2011 Dec;226(12):3219-24. doi: 10.1002/jcp.22682. J Cell Physiol. 2011. PMID: 21351101

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

49 results

Search Page

Filters